Nyhetsrum - PILA PHARMA | beQuoted Nyheter

Pressmeddelanden

2026-01-27 08:55

PILA PHARMA: INVITATION TO LIVE Q&A TODAY, JANUARY 27, REGARDING PRECLINICAL STUDIES AND UPCOMING CLINICAL STUDIES PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibitor, today hosts an onlin...

2026-01-26 11:00

REG MAR

PILA PHARMA SIGNS WITH NEW CLINICAL CRO TO PREPARE FOR CLINICAL PHASE IN OBESITY AFTER PRECLINICAL OBESITY STUDIES Malmö, 26 January 2026 PILA PHARMA AB (publ) (FN STO: PILA) ("PILA PHARMA" or the "Company"), an innovative biotech company developing a novel oral, small molecule TRPV1 inhibito...

2026-01-16 09:30

PILA PHARMA: CEO PARTICIPATED IN SWEDISH INVESTMENT PODCAST MARKET MAKERS PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, is delighted to...

2026-01-16 08:30

PILA PHARMA: ANALYST GROUP INITIATES NEW EQUITY RESEARCH COVERAGE - BASE CASE TARGET OF SEK 6.30 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, is deepening its...

2026-01-05 09:05

PILA PHARMA: INVITED TO PRESENT AT BIOTECH SHOWCASE / J.P MORGAN HEALTHCARE WEEK IN SAN FRANCISCO, JANUARY 13, 2026 PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, today shares tha...

2026-01-02 11:09

PILA PHARMA: CEO GUSTAV H. GRAM ACQUIRES ADDITIONAL SHARES PILA PHARMA AB (publ) (FN STO: PILA), an innovative biotech company developing a novel oral drug based on TRPV1 inhibition for treatment of obesity and diabetes, today announces...

Visa fler pressmeddelanden